Anavex Doses First Alzheimer’s Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
New York — January 12, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced dosing of the first patient in the Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, which are being developed as an oral therapy and oral drug combination for the potential treatment of Alzheimer’s disease. In…